Stevanato Group (NYSE:STVN) Sees Strong Trading Volume – Still a Buy?

Stevanato Group S.p.A. (NYSE:STVN) saw unusually-strong trading volume on Tuesday . Approximately 822,692 shares changed hands during mid-day trading, an increase of 20% from the previous session’s volume of 683,722 shares.The stock last traded at €14.58 and had previously closed at €13.81.

Analyst Ratings Changes

A number of equities analysts have recently commented on STVN shares. Citigroup dropped their target price on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Jefferies Financial Group set a $17.50 target price on Stevanato Group in a report on Tuesday, February 10th. Morgan Stanley dropped their price objective on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a report on Friday, March 6th. KeyCorp dropped their price objective on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Finally, Weiss Ratings cut Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

Stevanato Group Trading Up 6.3%

The stock has a fifty day moving average of €14.96 and a 200-day moving average of €19.72. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.26 and a current ratio of 1.76. The company has a market cap of $4.45 billion, a PE ratio of 25.29, a PEG ratio of 1.21 and a beta of 0.62.

Stevanato Group (NYSE:STVN) last issued its earnings results on Saturday, February 14th. The company reported €0.18 earnings per share for the quarter. The business had revenue of €346.50 million during the quarter. Stevanato Group had a return on equity of 10.44% and a net margin of 11.83%. Sell-side analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Institutional Trading of Stevanato Group

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. grew its holdings in Stevanato Group by 10.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,923,632 shares of the company’s stock worth $78,944,000 after acquiring an additional 368,792 shares during the period. TimesSquare Capital Management LLC grew its holdings in Stevanato Group by 7.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 3,500,321 shares of the company’s stock valued at $70,426,000 after purchasing an additional 232,645 shares during the period. Thrivent Financial for Lutherans grew its holdings in Stevanato Group by 7.1% in the third quarter. Thrivent Financial for Lutherans now owns 2,372,390 shares of the company’s stock valued at $61,089,000 after purchasing an additional 156,733 shares during the period. Bamco Inc. NY grew its holdings in Stevanato Group by 1.4% in the fourth quarter. Bamco Inc. NY now owns 2,001,724 shares of the company’s stock valued at $40,275,000 after purchasing an additional 27,965 shares during the period. Finally, Jennison Associates LLC grew its holdings in Stevanato Group by 13.7% in the fourth quarter. Jennison Associates LLC now owns 1,772,896 shares of the company’s stock valued at $35,671,000 after purchasing an additional 213,602 shares during the period.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.